Pfizer Raises 2026 Revenue Guidance on Strong Non-COVID Product Performance
Event summary
- Pfizer reported $15.0 billion in second-quarter 2026 revenues, a 1% year-over-year operational growth.
- The company raised its full-year 2026 revenue guidance by $500 million at the midpoint to a range of $60.5 to $62.5 billion.
- Launched and acquired products grew 18% operationally, driven by strong performance from Eliquis, Padcev, Vyndaqel family, and Lorbrena.
- Pfizer announced additional anticipated productivity enhancement savings of $2.5 billion associated with ongoing initiatives, expected to be realized from 2027 through 2029.
The big picture
Pfizer's raised guidance reflects a strategic shift towards non-COVID products, highlighting the company's ability to adapt to changing market dynamics. The focus on operational efficiency and cost savings initiatives underscores Pfizer's commitment to maintaining profitability amid evolving healthcare landscapes. The strong performance of launched and acquired products signals a robust pipeline that could drive future growth.
What we're watching
- Product Performance
- How the continued strength of non-COVID products will impact Pfizer's long-term revenue growth.
- Cost Savings Initiatives
- Whether Pfizer can sustain its productivity enhancement savings and achieve the targeted $2.5 billion in savings from 2027 through 2029.
- Strategic Alliances
- The pace at which Pfizer's strategic alliances, such as with Innovent Biologics, will drive future growth and innovation.
Related topics